NCT05305573View on ClinicalTrials.gov

Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
COVID-19SARS-CoV-2 Acute Respiratory Disease
Interventions
BIOLOGICAL

COVID-19 Vaccine HIPRA 40 ug/dose

Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)

BIOLOGICAL

Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection

Subjects will receive one injection of Comirnaty Vaccine

Trial Locations (7)

Unknown

Hospital HM Modelo, A Coruña

Hospital Gregorio Marañón, Madrid

Hospital HM Sanchinarro, Madrid

Hospital HM Puerta del Sur, Móstoles

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital HM Rosaleda, Santiago de Compostela

Complejo Hospitalario Universitario de Vigo, Vigo

Sponsors
All Listed Sponsors
lead

Hipra Scientific, S.L.U

INDUSTRY

NCT05305573 - Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. | Biotech Hunter | Biotech Hunter